Amarin Corp Plc (AMRN)

[Whalatane]

Wow Debbie So U think there’s NO chance Kaiser’s MITIGATE trial will show any benefit in CV risk reduction
They have 2 yr CV dats on the first 500 enrolled…. And 2 yr data on at least 1,000 by mid 2023 when they wind this up

For those 1,000 followed for 2 yrs …. If there’s no separation in event lines by then in this high risk US population on 4 gms of Vascepa …. well U will be right .

Doubt generic V or combo will amount to anything
RESPECT EPA …. In my view … disappointing trial and hasn’t moved the needle …..
Kiwi